Patent-settlement deductibility permits compensatory foreign litigation payments, while exempt-income limits govern disallowance and book-profit adjustments.
Deductibility of a genuine compensatory patent-settlement payment is examined under section 37(1), with the payment characterised as revenue expenditure where it resolves foreign patent litigation, protects business interests, and involves no proven guilt or prohibited purpose under the applicable law. Related financing interest is treated as consequential to the settlement's allowability. The material also addresses transfer-pricing treatment of captive-power transfers and associated-enterprise transactions; the cap on section 14A disallowance at exempt income and exclusion from book-profit computation; business-promotion expenditure; foreign-tax credit verification; research-and-development deductions; and wealth-tax provisions in book-profit computation. Software expenditure remains capital where depreciation has been claimed and allowed.
Issues: (i) Whether the transfer-pricing adjustment for electricity transferred by the captive power plant to eligible units was sustainable; (ii) Whether disallowance under section 14A read with Rule 8D could exceed exempt dividend income and be added to book profit; (iii) Whether the Pfizer patent-settlement payment was deductible as business expenditure; (iv) Whether interest incurred on financing the Pfizer settlement was deductible; (v) Whether software expenditure was allowable as revenue expenditure; (vi) Whether disallowance of business-promotion gift expenditure was sustainable; (vii) Whether deduction for foreign taxes was to be granted; (viii) Whether relief granted on the Revenue's transfer-pricing adjustments concerning loans to associated enterprises and sales to associated enterprises was sustainable; (ix) Whether relief concerning weighted research-and-development deductions and allocation of research-and-development expenditure was sustainable; (x) Whether deletion of additions concerning wealth-tax provision under section 115JB and the Cephalon patent settlement was sustainable.
Issue (i): Whether the transfer-pricing adjustment for electricity transferred by the captive power plant to eligible units was sustainable.
Analysis: The issue was covered by the Tribunal's order in the assessee's own case for the preceding assessment year, with no change in facts or law.
Conclusion: The adjustment was deleted, in favour of the assessee.
Issue (ii): Whether disallowance under section 14A read with Rule 8D could exceed exempt dividend income and be added to book profit.
Analysis: The exempt dividend earned was lower than the disallowance computed. The disallowance was therefore confined to the exempt dividend amount. The section 14A disallowance was not liable to be imported into computation of book profit under section 115JB.
Conclusion: The disallowance was restricted to exempt dividend income and no corresponding addition to book profit was permissible, in favour of the assessee.
Issue (iii): Whether the Pfizer patent-settlement payment was deductible as business expenditure.
Analysis: The settlement was a genuine, negotiated resolution of private patent litigation without any final adjudication or admission of guilt. It was incurred to avoid continuing litigation and protect business interests. The payment was compensatory and revenue in character, not a penalty or expenditure for a purpose prohibited by law. For the relevant assessment year, Explanation 1 to section 37(1) did not extend to alleged violations of foreign law, and the later expansion of its scope could not operate retrospectively. The liability crystallised after the appointed date under a court-sanctioned demerger scheme and vested in the assessee.
Conclusion: The Pfizer settlement payment was allowable under section 37(1), in favour of the assessee.
Issue (iv): Whether interest incurred on financing the Pfizer settlement was deductible.
Analysis: The interest claim was consequential to the allowability of the underlying Pfizer settlement expenditure.
Conclusion: The interest deduction was allowable, in favour of the assessee.
Issue (v): Whether software expenditure was allowable as revenue expenditure.
Analysis: Depreciation on the software expenditure had already been claimed and allowed.
Conclusion: No interference with the treatment of the expenditure as capital was warranted, against the assessee.
Issue (vi): Whether disallowance of business-promotion gift expenditure was sustainable.
Analysis: The expenditure was connected with business activities and its genuineness was not disproved. A fifty per cent ad hoc disallowance solely for want of complete recipient particulars lacked cogent evidentiary basis.
Conclusion: The disallowance was directed to be deleted after verification of expenditure details, in favour of the assessee.
Issue (vii): Whether deduction for foreign taxes was to be granted.
Analysis: Verification of the foreign-tax claim was required.
Conclusion: The issue was remanded for verification and grant of eligible deduction.
Issue (viii): Whether relief granted on the Revenue's transfer-pricing adjustments concerning loans to associated enterprises and sales to associated enterprises was sustainable.
Analysis: The relief was consistent with binding coordinate-bench orders in the assessee's own earlier assessment years, without any changed factual or legal position.
Conclusion: The relief was sustained, in favour of the assessee.
Issue (ix): Whether relief concerning weighted research-and-development deductions and allocation of research-and-development expenditure was sustainable.
Analysis: The issues concerning specified research-and-development expenses, weighted deduction and allocation were covered by orders in the assessee's own earlier years, including a position affirmed by the High Court for one year.
Conclusion: The relief was sustained, in favour of the assessee.
Issue (x): Whether deletion of additions concerning wealth-tax provision under section 115JB and the Cephalon patent settlement was sustainable.
Analysis: Both matters were governed by coordinate-bench decisions in the assessee's own earlier cases, with no material change in facts or law.
Conclusion: The deletions were sustained, in favour of the assessee.
Final Conclusion: The assessee obtained relief on the captive-power transfer-pricing adjustment, the Pfizer settlement and related interest, section 14A and book-profit computation, and business-promotion expenditure, while software treatment was retained and the foreign-tax claim required verification; the Revenue's challenges to the relief granted by the first appellate authority did not succeed.
Ratio Decidendi: A genuine compensatory payment under an out-of-court settlement of foreign patent litigation, made without proven guilt to protect business interests, is deductible as revenue expenditure where the applicable version of section 37(1) does not cover alleged contraventions of foreign law.